How to Get AndroGel in Delaware: Prescriptions, Telehealth, and Pharmacies

What Is AndroGel and Why Delaware Patients Need a Prescription

AndroGel is a hydroalcoholic testosterone gel available in two concentrations, 1% and 1.62%, both FDA-approved for adult males with hypogonadism confirmed by clinical signs and low serum testosterone. Because testosterone is a DEA Schedule III controlled substance, no path to AndroGel exists without a valid prescription from a licensed prescriber. The FDA-approved labeling for AndroGel 1.62% specifies that diagnosis must rest on both clinical presentation and laboratory evidence, not on symptoms alone.

Male hypogonadism affects roughly 2.1% of men aged 40 to 79 years in community-based samples, with prevalence rising steeply after age 60 1. The Testosterone Trials (TTrials), a coordinated set of seven placebo-controlled studies in 788 men aged 65 and older with total testosterone below 275 ng/dL, found that one year of testosterone gel therapy significantly improved sexual function, physical performance, and bone density compared with placebo 2. The TTrials used a gel formulation and represent the largest high-quality evidence base for AndroGel-class products in older men.

Delaware classifies testosterone prescriptions under the same DEA Schedule III federal framework that applies nationwide. State law requires prescribers to hold an active Delaware Controlled Substance Registration (DCSR) alongside their DEA registration before writing Schedule III prescriptions for Delaware patients.

Required Labs Before a Delaware Prescriber Will Write an AndroGel Prescription

Two fasting, early-morning (7:00 a.m. to 10:00 a.m.) total testosterone measurements below the laboratory reference range are the foundation of any AndroGel prescription. The Endocrine Society's 2018 clinical practice guideline on male hypogonadism states: "We recommend making a diagnosis of androgen deficiency only in men with consistent symptoms and signs and unequivocally low serum testosterone levels" 3. A single low result is not sufficient because testosterone secretion is pulsatile and values fluctuate by 15 to 35% across a single morning 3.

Beyond testosterone, Delaware providers routinely order:

• LH and FSH to distinguish primary from secondary hypogonadism
• PSA (prostate-specific antigen) because AndroGel is contraindicated in men with suspected prostate or breast carcinoma 4
• Hematocrit and CBC given that testosterone increases erythropoiesis; the Endocrine Society guideline recommends withholding therapy if hematocrit exceeds 54% 3
• Comprehensive metabolic panel to screen for hepatic or renal contraindications
• SHBG (sex hormone-binding globulin) when total testosterone is borderline (275 to 400 ng/dL), so free testosterone can be calculated

Most commercial labs in Delaware (LabCorp, Quest, Christiana Care outpatient draw sites) return results within 24 to 48 hours. Telehealth platforms commonly mail an at-home requisition so patients draw locally before their video consultation.

How to Get an AndroGel Prescription in Delaware: Step-by-Step

Getting AndroGel in Delaware follows the same core sequence whether you use an in-person endocrinologist, a primary care physician, or a telehealth platform.

Step 1. Confirm symptoms. Common presentations include fatigue, reduced libido, erectile dysfunction, decreased muscle mass, and depressed mood. Documenting these before the visit shortens the consult.

Step 2. Order or present labs. Two morning testosterone values below 300 ng/dL (most Delaware labs use 264 to 916 ng/dL as the adult male reference range) alongside the panel above.

Step 3. Consult a prescriber. The prescriber must hold an active Delaware medical license and a DCSR. An initial video visit typically runs 20 to 40 minutes. The provider reviews symptoms, labs, cardiovascular history, and prostate history before writing.

Step 4. Receive the prescription. Delaware pharmacies accept electronic prescriptions for Schedule III substances under the state's participation in the DEA's Electronic Prescribing for Controlled Substances (EPCS) program.

Step 5. Fill at pharmacy or 503A compounder. Brand-name AndroGel at retail pharmacies averages $500 to $700 per month without insurance; GoodRx coupons can drop the 1% formulation to approximately $90 to $120 at Walmart or Costco pharmacies in Delaware. Compounded testosterone gel from a 503A pharmacy costs $30 to $80 monthly.

Step 6. Follow-up labs at 3 months. The Endocrine Society guideline recommends measuring testosterone 3 to 6 months after initiation to confirm mid-normal range achievement (450 to 700 ng/dL) and to recheck hematocrit and PSA 3.

Telehealth Providers Prescribing AndroGel in Delaware

Telehealth prescribing of AndroGel is legal in Delaware. The Delaware Division of Professional Regulation confirmed that telehealth practitioners must establish a valid provider-patient relationship before prescribing controlled substances, consistent with the federal Ryan Haight Online Pharmacy Consumer Protection Act requirements currently in force 5.

Several national telehealth platforms maintain Delaware-licensed prescribers and can issue AndroGel or compounded testosterone gel prescriptions. The typical telehealth pathway is:

1. Online intake form capturing symptom history and prior labs
2. At-home or local lab draw
3. Synchronous or asynchronous video review with a Delaware-licensed MD, DO, NP, or PA
4. Electronic prescription sent to the patient's chosen pharmacy or to the platform's partner 503A compounder

Patients using telehealth should verify that the platform's prescriber holds both a current Delaware medical or advanced practice license and an active DEA registration covering Delaware before consenting to the visit. Out-of-state prescribers who are not licensed in Delaware cannot legally prescribe AndroGel to Delaware residents, regardless of the platform.

The HealthRX clinical team uses the following framework to evaluate telehealth TRT platforms for Delaware patients:

| Criterion | Minimum Standard | |-----------|-----------------| | Prescriber Delaware license | Verified active on DELPROS database | | DEA Schedule III authority | Active federal DEA registration | | Lab vendor | CLIA-certified draw within 30 miles or home kit with accredited processing lab | | Follow-up cadence | Mandatory lab review at weeks 6-8 and month 3-6 | | Hematocrit monitoring | Stop-and-hold protocol at hematocrit > 54% | | Transfer policy | Written prescription provided on request within 72 hours |

Who Can Prescribe AndroGel in Delaware: MD, DO, NP, and PA Rules

Any Delaware-licensed prescriber with Schedule III DEA authority may write for AndroGel. That includes MDs, DOs, nurse practitioners (NPs), and physician assistants (PAs). Delaware grants NPs full practice authority under 24 Del. C. § 1902, meaning a collaborative agreement with a physician is not required for NPs to prescribe controlled substances independently. PAs in Delaware operate under a supervising physician arrangement per 24 Del. C. § 1770B, but the supervising physician need not co-sign each prescription.

Endocrinologists and urologists are specialists most comfortable managing hypogonadism long-term. Primary care physicians (family medicine, internal medicine) handle the majority of TRT prescriptions nationally. The American Urological Association's 2018 guidelines on testosterone deficiency state that "testosterone deficiency is a well-established medical condition and is FDA-approved for symptomatic men with low serum testosterone" 6.

AndroGel Pharmacy Access in Delaware: Retail and 503A Compounding

Delaware retail pharmacies stocking AndroGel include major chains (CVS, Walgreens, Rite Aid, Walmart Pharmacy) and independent pharmacies. Because AndroGel is Schedule III, pharmacies must maintain DEA registrations and log each dispensed quantity in the Delaware Prescription Monitoring Program (PMP) managed by the Delaware Division of Substance Abuse and Mental Health.

503A compounding pharmacies are state-licensed pharmacies that prepare patient-specific medications from bulk active pharmaceutical ingredients. They may legally compound testosterone gel (typically at concentrations of 1%, 1.62%, 2%, or custom strengths) and ship to Delaware patients under a valid prescription. Unlike 503B outsourcing facilities, 503A pharmacies cannot manufacture in advance or sell wholesale; each batch must correspond to a specific prescription 7.

Compounded testosterone gel is not bioequivalent-rated against brand AndroGel by the FDA, so switching between a brand and a compounded product requires prescriber review. The cost difference is substantial: compounded testosterone 1.62% gel often costs $35 to $75 monthly versus $500 to $700 for brand AndroGel without insurance coverage.

Delaware Medicaid and Insurance Prior Authorization for AndroGel

Delaware Medicaid covers AndroGel for male hypogonadism but requires prior authorization. The standard PA packet for Delaware Medicaid (administered through managed care organizations including Highmark and AmeriHealth) typically requests:

• Documentation of two testosterone values below the lab reference range with dates and collection times
• ICD-10 diagnosis code E29.1 (testicular hypofunction) or E23.0 (hypopituitarism) depending on etiology
• A statement that the patient has symptomatic hypogonadism, not merely low laboratory values
• PSA documentation for patients over 40 years of age
• Prescriber attestation that brand AndroGel is medically necessary if the PA request is for brand rather than generic testosterone gel

Commercial insurers in Delaware (Highmark Blue Cross Blue Shield Delaware, Aetna, UnitedHealthcare) apply similar criteria. Generic testosterone gel 1% (multiple manufacturers) is considerably more likely to receive Tier 2 or Tier 3 formulary placement without PA than brand AndroGel, which typically sits at Tier 4 or Tier 5 on commercial plans.

A 2020 analysis of testosterone therapy prior authorization requirements across 50 state Medicaid programs found that 34 states required PA, and the average time from submission to decision was 4.2 days for standard requests and 1.1 days for urgent requests 8. Delaware's managed care organizations generally follow the federal 72-hour standard review and 24-hour expedited review timelines under 42 C.F.R. § 438.210.

Transferring an Existing AndroGel Prescription to Delaware

Delaware residents moving from another state or switching pharmacies can transfer a Schedule III prescription under 21 U.S.C. § 829 and DEA regulations at 21 C.F.R. § 1306.25. The rules allow a one-time transfer of a Schedule III refillable prescription between pharmacies, provided:

• The receiving pharmacy is DEA-registered in Delaware
• The transferring pharmacy voids its own record at the time of transfer
• Both pharmacies document the transfer in writing or electronically

Electronic transfer via shared pharmacy software networks (PioneerRx, QS/1, Pharmacy HIS) is common at chain pharmacies. Patients transferring from out-of-state providers should confirm that the original prescriber holds an active DEA registration; some states issue DEA registrations tied to a practice address, and a prescriber who has relocated may need to update their registration before the transfer is valid.

If the original prescription has no remaining refills, a new Delaware prescriber must evaluate the patient and issue a fresh prescription. The new prescriber may request records from the prior provider to confirm diagnosis and monitoring history rather than requiring the patient to repeat all baseline labs from scratch.

Dosing and Application: What Delaware Patients Should Expect

The FDA-approved starting dose for AndroGel 1.62% is 40.5 mg (two pump actuations or two unit-dose packets) applied once daily to clean, dry, intact skin on the shoulders or upper arms. The 1% formulation starts at 50 mg (5 g of gel). Neither formulation should be applied to the genitals, abdomen, or chest.

Serum testosterone should be measured 14 days after initiation or dose change, collected 2 to 8 hours after application to capture peak levels 4. The dose may be increased to 81 mg (1.62%) or decreased to 20.25 mg based on that result. Maximum approved dose for 1.62% is 81 mg daily.

Transfer of testosterone to skin-contact partners or children is a documented safety concern. The FDA added a boxed warning to AndroGel labeling after reports of virilization in children following secondary exposure 4. Patients should wash hands with soap and water immediately after application, cover the application site with clothing, and shower before anticipated skin contact.

Monitoring Schedule After Starting AndroGel in Delaware

Regular monitoring is not optional. The Endocrine Society 2018 guideline specifies this minimum schedule 3:

• 3 to 6 months post-initiation: Total testosterone (mid-range target 450 to 700 ng/dL), hematocrit, PSA
• 12 months: Repeat full panel plus bone mineral density if baseline was low
• Annually thereafter: Testosterone, hematocrit, PSA, and symptom reassessment

Hematocrit above 54% requires dose reduction or temporary discontinuation. PSA rising more than 1.4 ng/mL above baseline within 12 months, or exceeding 4.0 ng/mL in absolute terms, warrants urology referral per the AUA 2018 guideline 6.

Patients using Delaware telehealth platforms should confirm that the platform includes mandatory lab-review visits; some subscription-based services send labs but do not proactively follow up on out-of-range hematocrit values, which carries real clinical risk.

Side Effects and Contraindications Delaware Prescribers Evaluate

AndroGel is contraindicated in men with known or suspected breast or prostate cancer, women (particularly those who are pregnant), and patients with hypersensitivity to any component of the gel, including alcohol 4.

Common side effects reported in AndroGel clinical trials at rates above 5% include application site reactions (pruritus, blistering, erythema), increased hematocrit, acne, and increased PSA. Gynecomastia occurs through peripheral aromatization of testosterone to estradiol; co-prescribing an aromatase inhibitor such as anastrozole 0.5 mg twice weekly is sometimes used off-label when estradiol rises above 40 pg/mL.

The TRAVERSE trial (N=5,246), published in 2023, found that testosterone replacement therapy in middle-aged and older men with hypogonadism and high cardiovascular risk did not significantly increase major adverse cardiovascular events (MACE) compared with placebo over a median follow-up of 33 months (hazard ratio 0.96 to 95% CI 0.78 to 1.17) 9. The trial also observed a higher rate of atrial fibrillation, acute kidney injury, and pulmonary embolism in the testosterone group, findings that inform how Delaware prescribers counsel patients with pre-existing cardiovascular risk.

Cost and Savings Programs for AndroGel in Delaware

AbbVie offers a savings card for commercially insured patients that can reduce out-of-pocket cost for AndroGel 1.62% to as little as $0 for eligible patients. The card does not apply to Medicaid, Medicare Part D, or other government-funded programs.

GoodRx pricing at Delaware pharmacies (January 2025 data) shows:

• AndroGel 1.62% 75 g (30-day supply): $480 to $620 retail; $90 to $140 with GoodRx coupon at select pharmacies
• Generic testosterone gel 1% 150 g (30-day supply): $60 to $90 with coupon
• Compounded testosterone gel 1.62% 30-day supply from 503A pharmacy: $35 to $80 shipped

Patients on Delaware Medicaid who receive PA approval typically pay a nominal copay ($3 to $5) per fill at participating pharmacies.